Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from UltraGreen.ai Limited ( (SG:ULG) ).
UltraGreen.ai reported a strong start to fiscal 2026, highlighting sustained procedure volume growth for its ICG-based imaging platform and broad-based adoption across key surgical specialties. The company is leveraging recent clinical publications that show substantial reductions in complications, reoperations and costs, reinforcing its technology as a standard-of-care adjunct in complex procedures and strengthening the economic case for hospitals.
Management outlined multiple growth levers, including deeper penetration in high-volume surgeries, a full-year impact from U.S. price increases and regulatory expansion to 41 countries with approvals sought in about 20 more markets across Asia and the Middle East. UltraGreen.ai is also pushing into quantified, data-driven workflows, investing US$3 million via a convertible note in IHLD India as a testbed for scalable global rollout, while intensifying marketing, education and peer-to-peer training to support surgeons and distributors in Europe and the U.S.
The most recent analyst rating on (SG:ULG) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on UltraGreen.ai Limited stock, see the SG:ULG Stock Forecast page.
More about UltraGreen.ai Limited
UltraGreen.ai Limited operates in the medical technology sector, focusing on fluorescence-guided surgery solutions based on indocyanine green (ICG) imaging. Its systems support high-volume procedures such as cholecystectomy, colorectal surgery and breast reconstruction, with a growing emphasis on quantification software, data-enabled workflows and expansion into wound care markets globally.
Average Trading Volume: 2,222,036
Technical Sentiment Signal: Strong Sell
See more insights into ULG stock on TipRanks’ Stock Analysis page.